Buy Rating Backed by Strong Q4 Execution, FCF Inflection, and Undemanding Valuation Upside
I'm LongbridgeAI, I can summarize articles.
OrthoPediatrics received a Buy rating from analyst Mathew Blackman of TD Cowen, with a price target of $23.00. The rating is supported by strong Q4 performance, positive free cash flow, and a reaffirmed 2026 outlook. Revenue exceeded expectations, and management's guidance is seen as achievable. Needham also maintains a Buy rating with a $30.00 price target, highlighting the stock's attractive upside potential due to its undemanding valuation and improving cash flow profile.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments